Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > OA & Back pain worth

<< Previous

Bullboard Posts

Next >>

Comment by MrMugsyon Mar 19, 2021 1:08pm

197 Views

Post# 32838715

RE:RE:RE:RE:RE:RE:RE:RE:OA & Back pain worth

Alex1967 wrote:
How about south America?

Good question - I realized I didn't include that ... after I hit the "post" button.

Based on global pharma sales, I'll guess South America, Central America and the Islands are worth $60M + royalties ... and ... Australia/NZ are worth $20M + royalties (right now).

Just me taking a stab at it.

<< Previous

Bullboard Posts

Next >>

Rich TV Live's Stocks to Watch this week (Nov. 22, 2024)